Status:
UNKNOWN
The Effect of Dietary Intervation on Endothelial Glycocalyx in COVID-19 Patients.
Lead Sponsor:
University of Athens
Conditions:
COVID-19
Endothelial Dysfunction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The food supplement Endocalyx is considered to support the endothelial glycocalyx integrity by supplying sulfated polysaccharides, anti-oxidant enzymes and additional substrates for glycocalyx synthes...
Detailed Description
Sixty patients who have been hospitalized due to COVID-19 infection will be randomized to receive food supplement Endocalyx (4 capsules per day) (n=30) or placebo (n=30) for 4 consecutive months.
Eligibility Criteria
Inclusion
- caucasian patients
- hospitalization for COVID-19 infection
- diagnosis of COVID-19 proven by PCR
Exclusion
- Pregnancy and breastfeeding
- Foreseen inability to attend scheduled visits
- History of acute coronary syndrome. Coronary artery disease will be excluded by a clinical history, examination and electrocardiogram.
- Moderate or severe valve disease
- Primary cardiomyopathies
- Chronic obstructive pulmonary disease
- Asthma
- Chronic kidney disease (estimated glomerular filtration rate \[eGFR\] ≤60 ml/min/1.73 m2)
- Liver failure
- Malignancies
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05185934
Start Date
June 1 2022
End Date
January 30 2024
Last Update
May 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Attikon" University General Hospital
Athens, Attica, Greece, 12462